In an expert view piece, Ronald Wisor and Hein van den Bos — partners at the global law firm Hogan Lovells — discuss the challenges created by Europe's evolving 1 June 2018
Francine Lane is the Vice President of Global Transparency at TrialScope, where she supports clients in meeting and exceeding global disclosure expectations. Sh 17 May 2018
Christopher Bouton is the founder and CEO of Vyasa, a provider of deep learning software for the life sciences and healthcare industries. In our latest look at 9 May 2018
Chris Nave, CEO of the Medical Research Commercialization Fund and Managing Director at the VC firm Brandon Capital, shares his thoughts on promising landscape 4 May 2018
Ian Churcher is VP for drug discovery at Benevolent and a former GSK director and University of Oxford professor. Writing exclusively for The Pharma Letter, he 27 April 2018
Reda Guiha, regional president of international developed markets for Pfizer Vaccines, writes a topical Expert View piece timed to coincide with World Immunizat 25 April 2018
An Expert View piece on the difficulties involved in drug development in an 'intractable epidemic' from Christian Wandersee, chief executive and co-founder of V 18 April 2018
Matthew Majewski is a vice president in CRA’s Life Sciences Practice. He has a track record of providing life science clients with analytically based solutions 6 April 2018
Business, technical, and financial incentives are driving the rapid adoption of cloud-based, commercially available solutions in pharmaceutical research and ope 27 March 2018
Ogilvy Healthworld's fourth annual report analyzing social media usage across pharma reveals that Novo Nordisk, Johnson & Johnson and Novartis are leading the c 21 March 2018
Michael Jewell, healthcare partner at sell-side mergers and acquisitions (M&A) advisory firm Cavendish Corporate Finance, writes an Expert View piece on 1 March 2018
Edward Jones, a policy and communications consultant at independent London-based strategic communications firm GK Strategy, an, considers the opportunities pres 20 February 2018
Chris Miller, scientific lead at 3D Communications, provides his perspective on the regulatory challenges facing pharmaceutical companies that are developing op 14 February 2018
In the second of two Expert View columns to whet the appetite for the eyeforpharma Barcelona event in March, Sanofi’s Chief Data Officer (CDO), Milind Kamkolkar 31 January 2018
In a highly informative and useful Expert View piece.Heather Longden.senior marketing manager for informatics regulatory compliance at the analytical laboratory 26 January 2018
In the first of two Expert View columns to whet the appetite for the eyeforpharma Barcelona event in March, senior executives from Boehringer Ingelheim, Teva Ph 24 January 2018
The cost of prescription drugs is at the forefront of discussions among patients.advocacy groups.prescribers.payers.pharmaceutical companies.and policy makers.O 19 January 2018
Andrew Rut, chief executive of MyMeds&Me, a provider of adverse event and product quality capture software, considers in an Expert View piece how pharma’s abili 9 January 2018
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.